Critical  ||| S:0 E:9 ||| JJ
care  ||| S:9 E:14 ||| NN
normality ||| S:14 E:23 ||| NNS
:  ||| S:23 E:25 ||| :
individualized  ||| S:25 E:40 ||| FW
versus  ||| S:40 E:47 ||| FW
protocolized  ||| S:47 E:60 ||| FW
care  ||| S:60 E:65 ||| NN
Patients  ||| S:65 E:74 ||| NNS
with  ||| S:74 E:79 ||| IN
critical  ||| S:79 E:88 ||| JJ
illness  ||| S:88 E:96 ||| NNS
are  ||| S:96 E:100 ||| VBP
heterogeneous ||| S:100 E:113 ||| JJ
,  ||| S:113 E:115 ||| ,
with  ||| S:115 E:120 ||| IN
differing  ||| S:120 E:130 ||| VBG
physiologic  ||| S:130 E:142 ||| JJ
requirements  ||| S:142 E:155 ||| NNS
over  ||| S:155 E:160 ||| IN
time ||| S:160 E:164 ||| NN
.  ||| S:164 E:166 ||| .
Goal-directed  ||| S:166 E:180 ||| JJ
therapy  ||| S:180 E:188 ||| NN
in  ||| S:188 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
emergency  ||| S:195 E:205 ||| NN
room  ||| S:205 E:210 ||| NN
demonstrates  ||| S:210 E:223 ||| VBZ
that  ||| S:223 E:228 ||| DT
protocolized  ||| S:228 E:241 ||| JJ
care  ||| S:241 E:246 ||| NN
could  ||| S:246 E:252 ||| MD
result  ||| S:252 E:259 ||| VB
in  ||| S:259 E:262 ||| IN
improved  ||| S:262 E:271 ||| JJ
outcomes ||| S:271 E:279 ||| NNS
.  ||| S:279 E:281 ||| .
Subsequent  ||| S:281 E:292 ||| JJ
studies  ||| S:292 E:300 ||| NNS
have  ||| S:300 E:305 ||| VBP
confirmed  ||| S:305 E:315 ||| VBN
benefit  ||| S:315 E:323 ||| NN
with  ||| S:323 E:328 ||| IN
such  ||| S:328 E:333 ||| PDT
a  ||| S:333 E:335 ||| DT
bundle-based  ||| S:335 E:348 ||| JJ
approach  ||| S:348 E:357 ||| NN
in  ||| S:357 E:360 ||| IN
the  ||| S:360 E:364 ||| DT
emergency  ||| S:364 E:374 ||| NN
room  ||| S:374 E:379 ||| NN
and  ||| S:379 E:383 ||| CC
in  ||| S:383 E:386 ||| IN
preoperative  ||| S:386 E:399 ||| NN
and  ||| S:399 E:403 ||| CC
postoperative  ||| S:403 E:417 ||| JJ
scenarios ||| S:417 E:426 ||| NNS
.  ||| S:426 E:428 ||| .
However ||| S:428 E:435 ||| RB
,  ||| S:435 E:437 ||| ,
this  ||| S:437 E:442 ||| DT
cannot  ||| S:442 E:449 ||| NN
be  ||| S:449 E:452 ||| VB
necessarily  ||| S:452 E:464 ||| RB
extrapolated  ||| S:464 E:477 ||| VBN
to  ||| S:477 E:480 ||| TO
the  ||| S:480 E:484 ||| DT
medium-term  ||| S:484 E:496 ||| JJ
and  ||| S:496 E:500 ||| CC
long-term  ||| S:500 E:510 ||| JJ
care  ||| S:510 E:515 ||| NN
pathway  ||| S:515 E:523 ||| NN
of  ||| S:523 E:526 ||| IN
the  ||| S:526 E:530 ||| DT
critically  ||| S:530 E:541 ||| JJ
ill  ||| S:541 E:545 ||| JJ
patient ||| S:545 E:552 ||| NN
.  ||| S:552 E:554 ||| .
It  ||| S:554 E:557 ||| PRP
is  ||| S:557 E:560 ||| VBZ
likely  ||| S:560 E:567 ||| RB
that  ||| S:567 E:572 ||| IN
the  ||| S:572 E:576 ||| DT
development  ||| S:576 E:588 ||| NN
of  ||| S:588 E:591 ||| IN
mitochondrial  ||| S:591 E:605 ||| JJ
dysfunction  ||| S:605 E:617 ||| NN
could  ||| S:617 E:623 ||| MD
result  ||| S:623 E:630 ||| VB
in  ||| S:630 E:633 ||| IN
goal-directed  ||| S:633 E:647 ||| JJ
types  ||| S:647 E:653 ||| NNS
of  ||| S:653 E:656 ||| IN
approaches  ||| S:656 E:667 ||| NNS
being  ||| S:667 E:673 ||| VBG
detrimental ||| S:673 E:684 ||| NNS
.  ||| S:684 E:686 ||| .
Equally ||| S:686 E:693 ||| RB
,  ||| S:693 E:695 ||| ,
arterial  ||| S:695 E:704 ||| JJ
pressure  ||| S:704 E:713 ||| NN
aims  ||| S:713 E:718 ||| NNS
are  ||| S:718 E:722 ||| VBP
likely  ||| S:722 E:729 ||| JJ
to  ||| S:729 E:732 ||| TO
be  ||| S:732 E:735 ||| VB
considerably  ||| S:735 E:748 ||| RB
different  ||| S:748 E:758 ||| JJ
as  ||| S:758 E:761 ||| IN
the  ||| S:761 E:765 ||| DT
patient ||| S:765 E:772 ||| NN
's  ||| S:772 E:775 ||| POS
physiology  ||| S:775 E:786 ||| JJ
moves  ||| S:786 E:792 ||| NNS
toward  ||| S:792 E:799 ||| IN
hibernation ||| S:799 E:810 ||| NN
.  ||| S:810 E:812 ||| .
The  ||| S:812 E:816 ||| DT
agents  ||| S:816 E:823 ||| NNS
we  ||| S:823 E:826 ||| PRP
utilize  ||| S:826 E:834 ||| VBD
as  ||| S:834 E:837 ||| IN
sedative  ||| S:837 E:846 ||| NN
and  ||| S:846 E:850 ||| CC
pressor  ||| S:850 E:858 ||| JJ
agents  ||| S:858 E:865 ||| NNS
have  ||| S:865 E:870 ||| VBP
considerable  ||| S:870 E:883 ||| JJ
effects  ||| S:883 E:891 ||| NNS
on  ||| S:891 E:894 ||| IN
immune  ||| S:894 E:901 ||| JJ
function  ||| S:901 E:910 ||| NN
and  ||| S:910 E:914 ||| CC
the  ||| S:914 E:918 ||| DT
inflammatory  ||| S:918 E:931 ||| JJ
profile ||| S:931 E:938 ||| NN
,  ||| S:938 E:940 ||| ,
and  ||| S:940 E:944 ||| CC
should  ||| S:944 E:951 ||| MD
be  ||| S:951 E:954 ||| VB
considered  ||| S:954 E:965 ||| VBN
as  ||| S:965 E:968 ||| IN
part  ||| S:968 E:973 ||| NN
of  ||| S:973 E:976 ||| IN
the  ||| S:976 E:980 ||| DT
total  ||| S:980 E:986 ||| JJ
clinical  ||| S:986 E:995 ||| JJ
picture ||| S:995 E:1002 ||| NN
.  ||| S:1002 E:1004 ||| .
The  ||| S:1004 E:1008 ||| DT
role  ||| S:1008 E:1013 ||| NN
of  ||| S:1013 E:1016 ||| IN
gut  ||| S:1016 E:1020 ||| JJ
failure  ||| S:1020 E:1028 ||| NN
in  ||| S:1028 E:1031 ||| IN
driving  ||| S:1031 E:1039 ||| VBG
inflammation  ||| S:1039 E:1052 ||| NN
is  ||| S:1052 E:1055 ||| VBZ
considerable ||| S:1055 E:1067 ||| JJ
,  ||| S:1067 E:1069 ||| ,
and  ||| S:1069 E:1073 ||| CC
the  ||| S:1073 E:1077 ||| DT
drive  ||| S:1077 E:1083 ||| NN
to  ||| S:1083 E:1086 ||| TO
feed  ||| S:1086 E:1091 ||| VB
enterally ||| S:1091 E:1100 ||| NNS
,  ||| S:1100 E:1102 ||| ,
regardless  ||| S:1102 E:1113 ||| RB
of  ||| S:1113 E:1116 ||| IN
aspirate  ||| S:1116 E:1125 ||| JJ
volume ||| S:1125 E:1131 ||| NN
,  ||| S:1131 E:1133 ||| ,
may  ||| S:1133 E:1137 ||| MD
be  ||| S:1137 E:1140 ||| VB
detrimental  ||| S:1140 E:1152 ||| VBN
in  ||| S:1152 E:1155 ||| IN
those  ||| S:1155 E:1161 ||| DT
with  ||| S:1161 E:1166 ||| IN
degrees  ||| S:1166 E:1174 ||| NNS
of  ||| S:1174 E:1177 ||| IN
ileus ||| S:1177 E:1182 ||| NN
,  ||| S:1182 E:1184 ||| ,
which  ||| S:1184 E:1190 ||| WDT
is  ||| S:1190 E:1193 ||| VBZ
often  ||| S:1193 E:1199 ||| RB
a  ||| S:1199 E:1201 ||| DT
difficult  ||| S:1201 E:1211 ||| JJ
diagnosis  ||| S:1211 E:1221 ||| NN
in  ||| S:1221 E:1224 ||| IN
the  ||| S:1224 E:1228 ||| DT
critically  ||| S:1228 E:1239 ||| JJ
ill ||| S:1239 E:1242 ||| NN
.  ||| S:1242 E:1244 ||| .
The  ||| S:1244 E:1248 ||| DT
pathogenesis  ||| S:1248 E:1261 ||| NN
of  ||| S:1261 E:1264 ||| IN
liver  ||| S:1264 E:1270 ||| JJ
dysfunction  ||| S:1270 E:1282 ||| NN
may  ||| S:1282 E:1286 ||| MD
be ||| S:1286 E:1288 ||| VB
,  ||| S:1288 E:1290 ||| ,
at  ||| S:1290 E:1293 ||| IN
least  ||| S:1293 E:1299 ||| JJS
in  ||| S:1299 E:1302 ||| IN
part ||| S:1302 E:1306 ||| NN
,  ||| S:1306 E:1308 ||| ,
related  ||| S:1308 E:1316 ||| VBN
to  ||| S:1316 E:1319 ||| TO
venous  ||| S:1319 E:1326 ||| VB
engorgement  ||| S:1326 E:1338 ||| NNS
that  ||| S:1338 E:1343 ||| WDT
will  ||| S:1343 E:1348 ||| MD
contribute  ||| S:1348 E:1359 ||| VB
toward  ||| S:1359 E:1366 ||| IN
portal  ||| S:1366 E:1373 ||| JJ
hypertension  ||| S:1373 E:1386 ||| NN
and  ||| S:1386 E:1390 ||| CC
gut  ||| S:1390 E:1394 ||| JJ
edema ||| S:1394 E:1399 ||| NN
.  ||| S:1399 E:1401 ||| .
This ||| S:1401 E:1405 ||| DT
,  ||| S:1405 E:1407 ||| ,
in  ||| S:1407 E:1410 ||| IN
association  ||| S:1410 E:1422 ||| NN
with  ||| S:1422 E:1427 ||| IN
loss  ||| S:1427 E:1432 ||| NN
of  ||| S:1432 E:1435 ||| IN
the  ||| S:1435 E:1439 ||| DT
hepatosplanchnic  ||| S:1439 E:1456 ||| JJ
buffer  ||| S:1456 E:1463 ||| NN
response ||| S:1463 E:1471 ||| NN
,  ||| S:1471 E:1473 ||| ,
it  ||| S:1473 E:1476 ||| PRP
is  ||| S:1476 E:1479 ||| VBZ
likely  ||| S:1479 E:1486 ||| JJ
to  ||| S:1486 E:1489 ||| TO
contribute  ||| S:1489 E:1500 ||| VB
to  ||| S:1500 E:1503 ||| TO
venous  ||| S:1503 E:1510 ||| VB
pooling  ||| S:1510 E:1518 ||| VBN
in  ||| S:1518 E:1521 ||| IN
the  ||| S:1521 E:1525 ||| DT
abdominal  ||| S:1525 E:1535 ||| JJ
cavity ||| S:1535 E:1541 ||| NN
,  ||| S:1541 E:1543 ||| ,
impaired  ||| S:1543 E:1552 ||| VBN
venous  ||| S:1552 E:1559 ||| JJ
return ||| S:1559 E:1565 ||| NN
,  ||| S:1565 E:1567 ||| ,
and  ||| S:1567 E:1571 ||| CC
decreased  ||| S:1571 E:1581 ||| VBD
central  ||| S:1581 E:1589 ||| JJ
blood  ||| S:1589 E:1595 ||| NN
volumes ||| S:1595 E:1602 ||| NNS
.  ||| S:1602 E:1604 ||| .
Therapies  ||| S:1604 E:1614 ||| JJ
such  ||| S:1614 E:1619 ||| JJ
as  ||| S:1619 E:1622 ||| IN
those  ||| S:1622 E:1628 ||| DT
used  ||| S:1628 E:1633 ||| VBN
in  ||| S:1633 E:1636 ||| IN
small-for-size  ||| S:1636 E:1651 ||| JJ
syndrome  ||| S:1651 E:1660 ||| NN
may  ||| S:1660 E:1664 ||| MD
have  ||| S:1664 E:1669 ||| VB
a  ||| S:1669 E:1671 ||| DT
role  ||| S:1671 E:1676 ||| NN
in  ||| S:1676 E:1679 ||| IN
the  ||| S:1679 E:1683 ||| DT
chronic  ||| S:1683 E:1691 ||| JJ
stages  ||| S:1691 E:1698 ||| NNS
of  ||| S:1698 E:1701 ||| IN
septic  ||| S:1701 E:1708 ||| JJ
vascular  ||| S:1708 E:1717 ||| JJ
failure ||| S:1717 E:1724 ||| NN
.  ||| S:1724 E:1726 ||| .
